RELMADA THERAPEUTICS, INC. (RLMD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 08-31. Amounts in USD.

Revenue Quarterly

0 2.5K 5K 7.5K Q2 '12: 6K Q3 '12: 400 Q4 '12: 1.5K Q1 '13: 2.1K Q2 '13: 2.3K Q3 '13: 634 Q4 '13: 0 Q1 '14: 1.9K Q2 '14: 682 Q2 '12 Q4 '12 Q2 '13 Q4 '13 Q2 '14

Gross Profit Quarterly

-600 0 600 1.2K 1.8K Q2 '12: 1.5K Q3 '12: 108 Q4 '12: 517 Q1 '13: 299 Q2 '13: 482 Q3 '13: 312 Q4 '13: 0 Q1 '14: 164 Q2 '14: -3 Q2 '12 Q4 '12 Q2 '13 Q4 '13 Q2 '14

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '12: -439 Q2 '12: -503 Q3 '12: -2.5K Q4 '12: -8.6K Q1 '13: -9K Q2 '13: -4.1K Q3 '13: -600.9K Q3 '13: -19.5K Q4 '13: -12.4K Q1 '14: -481.8K Q1 '14: -14.4K Q2 '14: -5.1M Q2 '14: -3.1K Q3 '14: -711.9K Q4 '14: -12.2M Q1 '15: -3.7M Q2 '15: -4.4M Q3 '15: -4.6M Q4 '15: -4.4M Q1 '16: -4.6M Q2 '16: -5.7M Q3 '16: -2.7M Q4 '16: -3.1M Q1 '17: -1.6M Q2 '17: -1.5M Q3 '17: -2.3M Q4 '17: -1.8M Q1 '18: -980.9K Q2 '18: -1.5M Q3 '18: -2.5M Q4 '18: -1.9M Q1 '19: -2.4M Q2 '19: -3.5M Q3 '19: -2.7M Q4 '19: -4.1M Q1 '20: -3.7M Q2 '20: -4.6M Q3 '20: -10M Q4 '20: -12.8M Q1 '21: -17.2M Q2 '21: -20.9M Q3 '21: -22.4M Q4 '21: -26.5M Q1 '22: -42.7M Q2 '22: -34.2M Q3 '22: -38.3M Q4 '22: -45.5M Q1 '23: -38.7M Q2 '23: -38.7M Q3 '23: -28.2M Q4 '23: -26M Q1 '24: -22.7M Q2 '24: -26.8M Q3 '24: -23M Q4 '24: -18.8M Q1 '25: -23M Q2 '25: -19.1M Q3 '25: -18.2M Q4 '25: -10.2M Q1 '26: -10.3M Q2 '26: -20.3M Q3 '26: -19.5M Q4 '26: -15M Q3 '13 Q4 '14 Q4 '16 Q4 '18 Q4 '20 Q4 '22 Q4 '24 Q4 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q4 '11: -90 Q3 '12: -2.5K Q4 '12: -8.6K Q1 '13: -9K Q2 '13: -4.1K Q3 '13: -630.3K Q3 '13: -19.5K Q4 '13: -12.4K Q1 '14: -1.6M Q1 '14: -14.4K Q2 '14: -5.2M Q2 '14: -3.1K Q3 '14: 6.5M Q4 '14: -27.8M Q1 '15: -29.8M Q2 '15: 5.5M Q3 '15: -2.5M Q1 '16: 4.7M Q2 '16: -2.5M Q3 '16: -1.9M Q1 '17: -1.6M Q2 '17: -1M Q3 '17: -2M Q4 '17: -1.6M Q1 '18: -981.7K Q2 '18: -1.4M Q3 '18: -3.2M Q4 '18: -3.3M Q1 '19: -3.4M Q2 '19: -7.1M Q3 '19: -2.7M Q4 '19: -4.1M Q1 '20: -3.7M Q2 '20: -4.5M Q3 '20: -10.7M Q4 '20: -11.1M Q1 '21: -16.9M Q2 '21: -20.8M Q3 '21: -22.2M Q4 '21: -26.6M Q1 '22: -42.6M Q2 '22: -34.4M Q3 '22: -39.7M Q4 '22: -39.9M Q1 '23: -39.4M Q2 '23: -37.9M Q3 '23: -26.3M Q4 '23: -25.3M Q1 '24: -22M Q2 '24: -25.2M Q3 '24: -21.8M Q4 '24: -17.8M Q1 '25: -21.7M Q2 '25: -18.7M Q3 '25: -17.6M Q4 '25: -9.9M Q1 '26: -10.1M Q2 '26: -19.9M Q3 '26: -19.1M Q4 '26: -12.9M Q1 '13 Q2 '14 Q3 '16 Q4 '18 Q4 '20 Q4 '22 Q4 '24 Q4 '26

Cost of Revenue Quarterly

0 2K 4K 6K Q2 '12: 4.5K Q3 '12: 292 Q4 '12: 998 Q1 '13: 1.9K Q2 '13: 1.9K Q3 '13: 322 Q4 '13: 0 Q1 '14: 1.7K Q2 '14: 685 Q2 '12 Q4 '12 Q2 '13 Q4 '13 Q2 '14

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '12: -2K Q4 '12: -3.3K Q1 '13: 1.5K Q2 '13: -2.9K Q3 '13: -399.9K Q3 '13: -5K Q4 '13: -5.4K Q1 '14: -408.7K Q1 '14: -9.1K Q2 '14: -420.6K Q2 '14: -3.5K Q3 '14: -1M Q4 '14: -1.1M Q1 '15: -2.3M Q2 '15: -5M Q3 '15: -4.4M Q4 '15: -4.5M Q1 '16: -3.2M Q2 '16: -3.5M Q3 '16: -3.6M Q4 '16: -2.8M Q1 '17: -2.1M Q2 '17: -1.5M Q3 '17: -1.9M Q4 '17: -1M Q1 '18: -979K Q2 '18: -1.1M Q3 '18: -1.6M Q4 '18: -2.3M Q1 '19: -1.7M Q2 '19: -3.1M Q3 '19: -2M Q4 '19: -3.7M Q1 '20: -2.5M Q2 '20: -3.9M Q3 '20: -3.4M Q4 '20: -5M Q1 '21: -12.5M Q2 '21: -6.9M Q3 '21: -16.1M Q4 '21: -17.2M Q1 '22: -20.9M Q2 '22: -37.7M Q3 '22: -19.4M Q4 '22: -21.6M Q1 '23: -26.9M Q2 '23: -35.9M Q3 '23: -16.5M Q4 '23: -13.3M Q1 '24: -11.6M Q2 '24: -10.2M Q3 '24: -13M Q4 '24: -13.3M Q1 '25: -16.7M Q2 '25: -8.8M Q3 '25: -18.1M Q4 '25: -6.4M Q1 '26: -6.7M Q2 '26: -14.6M Q3 '26: -15.1M Q4 '26: -9.6M Q3 '13 Q4 '14 Q4 '16 Q4 '18 Q4 '20 Q4 '22 Q4 '24 Q4 '26

Free Cash Flow Quarterly

-6M -4M -2M 0 2M 4M 6M Q4 '13: -5.4K Q1 '14: -409.5K Q1 '14: -9.1K Q2 '14: -428.7K Q2 '14: -3.5K Q3 '14: -1M Q4 '14: -1.2M Q1 '15: -2.3M Q2 '15: -5M Q3 '15: -4.4M Q4 '15: -4.5M Q1 '16: -3.2M Q2 '16: -3.9M Q3 '16: -3.7M Q4 '16: -2.8M Q1 '17: -2.2M Q2 '17: -1.5M Q3 '17: -1.9M Q4 '17: -1M Q1 '18: -981.6K Q2 '18: -1.1M Q3 '18: -1.6M Q4 '18: -2.3M Q1 '14 Q2 '14 Q1 '15 Q4 '15 Q3 '16 Q2 '17 Q1 '18 Q4 '18

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q3 '13: 24M Q3 '14: 209.6M Q1 '15: 8.1M Q2 '15: 14.1M Q3 '15: 10.7M Q1 '16: 12.9M Q2 '16: 11.4M Q3 '16: 12M Q1 '17: 12M Q2 '17: 12M Q3 '17: 12M Q3 '21: 16.6M Q4 '21: 17.1M Q1 '22: 17.5M Q3 '22: 28.4M Q4 '22: 29.9M Q1 '23: 30.1M Q3 '23: 30.1M Q4 '23: 30.1M Q1 '24: 30.1M Q3 '24: 30.1M Q4 '24: 30.2M Q1 '25: 30.2M Q3 '25: 30.4M Q4 '25: 33.2M Q1 '26: 33.2M Q3 '26: 86.6M Q4 '26: 112.4M Q2 '15 Q3 '16 Q3 '21 Q4 '22 Q1 '24 Q3 '25 Q4 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q4 '12: 0.00 Q1 '13: 0.00 Q2 '13: 0.00 Q3 '15: -12.56 Q4 '15: -5.03 Q1 '16: -1.01 Q2 '16: -1.63 Q3 '16: -1.55 Q4 '17: -0.52 Q1 '18: -0.46 Q2 '18: -0.48 Q3 '18: -0.58 Q4 '18: -2.86 Q1 '19: -3.86 Q2 '19: -4.03 Q3 '19: -4.13 Q4 '19: -2.22 Q1 '20: -1.52 Q2 '20: -1.63 Q3 '20: -1.99 Q4 '20: -2.22 Q1 '21: -2.89 Q2 '21: -3.79 Q3 '21: -4.41 Q4 '21: -5.24 Q1 '22: -6.63 Q2 '22: -7.14 Q3 '22: -7.20 Q4 '22: -6.97 Q1 '23: -5.84 Q2 '23: -5.30 Q3 '23: -4.77 Q4 '23: -4.28 Q1 '24: -3.70 Q2 '24: -3.27 Q3 '24: -3.12 Q4 '24: -2.87 Q1 '25: -2.86 Q2 '25: -2.65 Q3 '25: -2.51 Q4 '25: -2.22 Q1 '26: -1.80 Q2 '26: -1.47 Q3 '26: -1.11 Q4 '26: -0.92 Q2 '13 Q4 '17 Q2 '19 Q4 '20 Q2 '22 Q4 '23 Q2 '25 Q4 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.